| Dr John Burnett Erskine, DPM | |
|
31 Hall Dr, Amherst, MA 01002-2751 | |
| (413) 256-8561 | |
| (413) 256-4421 |
| Full Name | Dr John Burnett Erskine |
|---|---|
| Gender | Male |
| Speciality | Podiatry |
| Experience | 31 Years |
| Location | 31 Hall Dr, Amherst, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184636193 | NPI | - | NPPES |
| 0365670 | Medicaid | MA | |
| 5148524 | Other | MA | AETNA |
| Y71113 | Other | MA | BCBSMA |
| 414250 | Other | MA | TUFTS |
| 1613044 | Other | MA | CIGNA |
| 38972 | Other | MA | HEALTH NEW ENGLAND |
| 67279 | Other | MA | FALLON |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Valley Medical Group Pc | 2365348851 | 104 |
News Archive
Researchers at the University of Bonn have found a way to stimulate the larynx muscles of mice using light. In the long term, this method could be an option for the treatment of laryngeal paralysis, which causes difficulties in phonation and breathing. Their findings will be published in the scientific journal "Nature Communications."
Anavex Life Sciences Corp. ("Anavex") (OTCQB: AVXL) today announced that it has been invited to submit a full grant application to the Alzheimer's Drug Discovery Foundation ("ADDF") for a Phase 2a trial of ANAVEX 2-73.
A drug recently approved by the Food & Drug Administration for the treatment of prostate cancer is proving to give some patients the gift of time. A new study shows abiraterone acetate extends the lives of men with the most advanced form of the disease by about four months.
Inhibiting a key immune response in mice during initial multi-drug treatment for tuberculosis could — paradoxically — shorten treatment time for the highly contagious lung infection according to new research from Johns Hopkins Children's Center and the Center for TB Research.
Cognitive behavioral therapy delivered in a primary care setting is a cost-effective way to treat adolescents with depression who decline or quickly stop using antidepressants, according to a Kaiser Permanente study published today in the journal Pediatrics.
› Verified 4 days ago
| Provider Name | Valley Medical Group Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1912924705 PECOS PAC ID: 2365348851 Enrollment ID: O20031208000239 |
News Archive
Researchers at the University of Bonn have found a way to stimulate the larynx muscles of mice using light. In the long term, this method could be an option for the treatment of laryngeal paralysis, which causes difficulties in phonation and breathing. Their findings will be published in the scientific journal "Nature Communications."
Anavex Life Sciences Corp. ("Anavex") (OTCQB: AVXL) today announced that it has been invited to submit a full grant application to the Alzheimer's Drug Discovery Foundation ("ADDF") for a Phase 2a trial of ANAVEX 2-73.
A drug recently approved by the Food & Drug Administration for the treatment of prostate cancer is proving to give some patients the gift of time. A new study shows abiraterone acetate extends the lives of men with the most advanced form of the disease by about four months.
Inhibiting a key immune response in mice during initial multi-drug treatment for tuberculosis could — paradoxically — shorten treatment time for the highly contagious lung infection according to new research from Johns Hopkins Children's Center and the Center for TB Research.
Cognitive behavioral therapy delivered in a primary care setting is a cost-effective way to treat adolescents with depression who decline or quickly stop using antidepressants, according to a Kaiser Permanente study published today in the journal Pediatrics.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr John Burnett Erskine, DPM Po Box 8019, Springfield, MA 01102-8000 Ph: (866) 431-4077 | Dr John Burnett Erskine, DPM 31 Hall Dr, Amherst, MA 01002-2751 Ph: (413) 256-8561 |
News Archive
Researchers at the University of Bonn have found a way to stimulate the larynx muscles of mice using light. In the long term, this method could be an option for the treatment of laryngeal paralysis, which causes difficulties in phonation and breathing. Their findings will be published in the scientific journal "Nature Communications."
Anavex Life Sciences Corp. ("Anavex") (OTCQB: AVXL) today announced that it has been invited to submit a full grant application to the Alzheimer's Drug Discovery Foundation ("ADDF") for a Phase 2a trial of ANAVEX 2-73.
A drug recently approved by the Food & Drug Administration for the treatment of prostate cancer is proving to give some patients the gift of time. A new study shows abiraterone acetate extends the lives of men with the most advanced form of the disease by about four months.
Inhibiting a key immune response in mice during initial multi-drug treatment for tuberculosis could — paradoxically — shorten treatment time for the highly contagious lung infection according to new research from Johns Hopkins Children's Center and the Center for TB Research.
Cognitive behavioral therapy delivered in a primary care setting is a cost-effective way to treat adolescents with depression who decline or quickly stop using antidepressants, according to a Kaiser Permanente study published today in the journal Pediatrics.
› Verified 4 days ago